Multi-Site Precision Promise Study Opens
Dr. Vincent Picozzi explains how Precision Promise clinical trial will use a personalized approach for pancreatic cancer patients.
Shedding More Light On Neoadjuvant Treatment
Dr. Matthew Katz reviews the study that compared neoadjuvant treatment with FOLFIRINOX versus gemcitabine/nab-paclitaxel for resectable pancreatic cancer.
PATHFINDER Blood Test Trial Focused on Early Detection
Dr. Minetta Liu is part of the team conducting a clinical trial to find biomarkers that will become an easy blood test for pancreatic cancer.
NALIRIFOX Shows Promise in Early Studies
Dr. Zev Wainberg describes the new combination NALIRIFOX, being tested in the NAPOLI-3 clinical trial for advanced pancreatic cancer patients.
Canadian Study NeoPancONE Focuses on Biomarker Validation
Dr. Jennifer Knox is leading the NeoPancONE trial for a biomarker that indicates which patients will respond better to certain chemotherapy before surgery.
GENERATE Trial Expands Eligibility
Dr. Sapna Syngal explains the expanded eligibility standards for the GENERATE Study for genetic testing of pancreatic cancer patients and relatives.
DIRECT Study Focuses on NanoKnife Technology
Dr. Daniel Holzwanger is part of the NanoKnife irreversible electroporation (IRE) study for stage III pancreatic cancer patients.
COMBATing Pancreatic Cancer
Dr. Manuel Hidalgo explains the COMBAT trial, which combines immunotherapy, a checkpoint inhibitor, and chemotherapy to attack pancreatic cancer.
High-Dose Vitamin C Targeting KRAS and BRAF in Pancreatic Cancer
Dr. Manish Shah leads a clinical trial of high-dose vitamin C targeting KRAS and BRAF mutations in solid-tumor cancers, including pancreatic cancer.
Challenge Grant Recipients Moving Forward
The Pancreatic Cancer Collective awarded four teams a second round of New Therapies Challenge Grants, to further develop new pancreatic cancer treatment.